Search results
Showing 8041 to 8055 of 9044 results
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Discontinued Reference number: GID-TA11421
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]
Discontinued Reference number: GID-TA10958
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Discontinued Reference number: GID-TA11020
In development Reference number: GID-TA11014 Expected publication date: TBC
Dexmedetomidine for treating agitation associated with schizophrenia [TSID10726]
In development Reference number: GID-TA11015 Expected publication date: TBC
Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]
Discontinued Reference number: GID-TA11240
Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]
Discontinued Reference number: GID-TA11178
Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]
Discontinued Reference number: GID-TA11173
Palforzia for treating peanut allergy in children and young people (TA769)
NICE has withdrawn this guidance. This is because Stallergenes Greer have discontinued the Palforzia initial dose escalation pack. No new people will start taking Palforzia in the UK. Healthcare professionals should discuss alternative treatment options. People currently having Palforzia will be able to continue until March 2027.
Discontinued Reference number: GID-TA11181
Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]
Discontinued Reference number: GID-TA11175
In development Reference number: GID-TA11457 Expected publication date: TBC
Terevalefim for treating delayed graft function after kidney transplant [ID1490]
Discontinued Reference number: GID-TA11098
Discontinued Reference number: GID-NG10387
Discontinued Reference number: GID-SGWAVE0700